Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas
机构：[1]Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China研究所北京市神经外科研究所首都医科大学附属天坛医院[2]Chinese Glioma Genome Atlas (CGGA), Beijing, China[3]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院
Aims The pyrosequencing (PSQ) has been regarded as the gold standard for MGMT promoter methylation testing in gliomas. However, various CpG combinations are currently used in clinical practice. We aimed to clarify how and how many CpGs combined is robust enough to predict MGMT mRNA expression and therapeutic prognosis of patients. Methods Total 223 patients with WHO III/IV gliomas were enrolled from Chinese Glioma Genome Atlas, including two independent cohorts, the eight-site cohort (with CpGs 75-82 tested) and the seven-site cohort (with CpGs 72-78 tested). Spearman's correlation and ROC curves were employed to investigate the value of different CpG combinations on predicting MGMT mRNA expression. The ROC curves and Kaplan-Meier steps were performed to compare the TMZ therapeutic prognostic values of different CpG combinations. Results The methylation level of all individual CpG and CpG combinations for the eleven CpGs (CpGs 72-82), significantly correlated to MGMT mRNA expression (Spearman, all P < 0.0001), could effectively predict the mRNA expression (AUC, 0.86-0.91 in the eight-site cohort, 0.83-0.90 in the seven-site cohort). Moreover, the correlation coefficients and the predictive values presented equivalent when four or more CpGs combinedly used (AUC, 0.88-0.90 in the eight-site cohort, 0.87-0.88 in the seven-site cohort). Finally, similar results were also observed when using selected CpG combinations to predict therapeutic prognosis of patients. Conclusions Four-CpG combinations of pyrosequencing are sufficient for evaluating the methylation status of MGMT and predicting therapeutic prognosis in gliomas.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81773208]; Beijing Nova ProgramBeijing Municipal Science & Technology Commission [Z16110004916082]
第一作者机构：[1]Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China[2]Chinese Glioma Genome Atlas (CGGA), Beijing, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China[2]Chinese Glioma Genome Atlas (CGGA), Beijing, China[3]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[*1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 TiantanXili, Dongcheng District, Beijing 100050, China
推荐引用方式(GB/T 7714)：
Chai Rui-Chao,Zhang Ke-Nan,Liu Yu-Qing,et al.Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas[J].CNS NEUROSCIENCE & THERAPEUTICS.2019,25(3):314-322.doi:10.1111/cns.13040.
APA：
Chai, Rui-Chao,Zhang, Ke-Nan,Liu, Yu-Qing,Wu, Fan,Zhao, Zheng...&Wang, Yong-Zhi.(2019).Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.CNS NEUROSCIENCE & THERAPEUTICS,25,(3)
MLA：
Chai, Rui-Chao,et al."Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas".CNS NEUROSCIENCE & THERAPEUTICS 25..3(2019):314-322
